Smad signaling pathway is a pivotal component of tissue inhibitor of metalloproteinases-3 regulation by transforming growth factor beta in human chondrocytes

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1783, Issue 9, 2008, Pages 1605-1612

  Qureshi, Hamid Yaqoob ^a   Ricci, Gemma ^a   Zafarullah, Muhammad ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Articular chondrocyte; Promoter analysis; RNA interference; Smad; Tissue inhibitor of metalloproteinases 3; Transforming growth factor beta

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA1; 6,7 DIMETHYL 2 (2E) 3 (1 METHYL 2 PHENYL 1H PYRROLO(2,3 B)PYRIDIN 3 YL PROP 2 ENOYL) 1,2,3,4 TETRAHYDROISOQUINOLINE HYDROCHLORIDE; 6,7-DIMETHYL-2-(2E)-3-(1-METHYL-2-PHENYL-1H-PYRROLO(2,3-B)PYRIDIN-3-YL-PROP-2-ENOYL)-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE; ISOQUINOLINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; BIOSYNTHESIS; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM;

CELLS, CULTURED; CHONDROCYTES; CHROMATIN IMMUNOPRECIPITATION; HUMANS; ISOQUINOLINES; PROMOTER REGIONS (GENETICS); PYRIDINES; PYRROLES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMAD PROTEINS; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSFORMING GROWTH FACTOR BETA;

EID: 49149123259     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.04.005     Document Type: Article

References (60)

1. Nagase H., and Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res. Ther. 5 (2003) 94-103
2. Bramono D.S., Richmond J.C., Weitzel P.P., Kaplan D.L., and Altman G.H. Matrix metalloproteinases and their clinical applications in orthopaedics. Clin. Orthop. Relat Res. (2004) 272-285
3. Wieland H.A., Michaelis M., Kirschbaum B.J., and Rudolphi K.A. Osteoarthritis. Nat. Rev. Drug Discov. 4 (2005) 331-344
4. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 (2003) 356-361
5. Verdier M.P., Seite S., Guntzer K., Pujol J.P., and Boumediene K. Immunohistochemical analysis of transforming growth factor beta isoforms and their receptors in human cartilage from normal and osteoarthritic femoral heads. Rheumatol. Int. 25 (2005) 118-124
6. Goldring M.B., Tsuchimochi K., and Ijiri K. The control of chondrogenesis. J. Cell. Biochem. 97 (2006) 33-44
7. Blaney Davidson E.N., van der Kraan P.M., and van den Berg W.B. TGF-beta and osteoarthritis. Osteoarthr. Cartil. 15 (2007) 597-604
8. Brandes M.E., Allen J.B., Ogawa Y., and Wahl S.M. Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J. Clin. Invest. 87 (1991) 1108-1113
9. Scharstuhl A., van Beuningen H.M., Vitters E.L., van der Kraan P.M., and van den Berg W.B. Loss of transforming growth factor counteraction on interleukin 1 mediated effects in cartilage of old mice. Ann. Rheum. Dis. 61 (2002) 1095-1098
10. Lotz M., Kekow J., and Carson D.A. Transforming growth factor-beta and cellular immune responses in synovial fluids. J. Immunol. 144 (1990) 4189-4194
11. Huber L.C., Distler O., Tarner I., Gay R.E., Gay S., and Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology. (Oxford) 45 (2006) 669-675
12. Bakker A.C., van de Loo F.A., van Beuningen H.M., Sime P., van Lent P.L., van der Kraan P.M., Richards C.D., and van den Berg W.B. Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. Osteoarthr. Cartil. 9 (2001) 128-136
13. Scharstuhl A., Vitters E.L., van der Kraan P.M., and van den Berg W.B. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum. 48 (2003) 3442-3451
14. Mi Z., Ghivizzani S.C., Lechman E., Glorioso J.C., Evans C.H., and Robbins P.D. Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor beta 1 into rabbit knees. Arthritis Res. Ther. 5 (2003) R132-R139
15. Pagnotto M.R., Wang Z., Karpie J.C., Ferretti M., Xiao X., and Chu C.R. Adeno-associated viral gene transfer of transforming growth factor-beta1 to human mesenchymal stem cells improves cartilage repair. Gene Ther. 14 (2007) 804-813
16. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115 (2002) 3719-3727
17. Lee M.H., Atkinson S., and Murphy G. Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J. Biol. Chem. 282 (2007) 6887-6898
18. Hashimoto G., Aoki T., Nakamura H., Tanzawa K., and Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett. 494 (2001) 192-195
19. Gendron C., Kashiwagi M., Hughes C., Caterson B., and Nagase H. TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett. 555 (2003) 431-436
20. Wei S., Kashiwagi M., Kota S., Xie Z., Nagase H., and Brew K. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme. J. Biol. Chem. 280 (2005) 32877-32882
21. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., Stephens P.E., Shelley C., Hutton M., Knauper V., Docherty A.J., and Murphy G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435 (1998) 39-44
22. Lee M.H., Verma V., Maskos K., Nath D., Knauper V., Dodds P., Amour A., and Murphy G. Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. Biochem. J. 364 (2002) 227-234
23. Mahmoodi M., Sahebjam S., Smookler D., Khokha R., and Mort J.S. Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am. J. Pathol. 166 (2005) 1733-1740
24. Sahebjam S., Khokha R., and Mort J.S. Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum. 56 (2007) 905-909
25. Mohammed F.F., Smookler D.S., and Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann. Rheum. Dis. 62 Suppl 2 (2003) ii43-ii47
26. van der Laan W.H., Quax P.H., Seemayer C.A., Huisman L.G., Pieterman E.J., Grimbergen J.M., Verheijen J.H., Breedveld F.C., Gay R.E., Gay S., Huizinga T.W., and Pap T. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther. 10 (2003) 234-242
27. Schmierer B., and Hill C.S. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat. Rev., Mol. Cell Biol. 8 (2007) 970-982
28. Parker W.L., Finnson K.W., Soe-Lin H., Knaus P., and Philip A. Expression and function of TbetaRII-B, a variant of the type II TGF-beta receptor, in human chondrocytes. Osteoarthr. Cartil. 15 (2007) 442-453
29. Sakou T., Onishi T., Yamamoto T., Nagamine T., Sampath T., and Ten Dijke P. Localization of Smads, the TGF-beta family intracellular signaling components during endochondral ossification. J. Bone Miner. Res. 14 (1999) 1145-1152
30. Yang X., Chen L., Xu X., Li C., Huang C., and Deng C.X. TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J. Cell Biol. 153 (2001) 35-46
31. Li W.Q., Qureshi H.Y., Liacini A., Dehnade F., and Zafarullah M. Transforming growth factor Beta1 induction of tissue inhibitor of metalloproteinases 3 in articular chondrocytes is mediated by reactive oxygen species. Free Radic. Biol. Med. 37 (2004) 196-207
32. Qureshi H.Y., Sylvester J., El Mabrouk M., and Zafarullah M. TGF-beta-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor. J. Cell. Physiol. 203 (2005) 345-352
33. Qureshi H.Y., Ahmad R., Sylvester J., and Zafarullah M. Requirement of phosphatidylinositol 3-kinase/Akt signaling pathway for regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-beta in human chondrocytes. Cell. Signal. 19 (2007) 1643-1651
34. Zeng Y., Rosborough R.C., Li Y., Gupta A.R., and Bennett J. Temporal and spatial regulation of gene expression mediated by the promoter for the human tissue inhibitor of metalloproteinases-3 (TIMP-3)-encoding gene. Dev. Dyn. 211 (1998) 228-237
35. Fu Y., O'Connor L.M., Shepherd T.G., and Nachtigal M.W. The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells. Biochem. Biophys. Res. Commun. 310 (2003) 391-397
36. Jinnin M., Ihn H., and Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol. Pharmacol. 69 (2006) 597-607
37. Piek E., Ju W.J., Heyer J., Escalante-Alcalde D., Stewart C.L., Weinstein M., Deng C., Kucherlapati R., Bottinger E.P., and Roberts A.B. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J. Biol. Chem. 276 (2001) 19945-19953
38. Blaney Davidson E.N., Vitters E.L., van der Kraan P.M., and van den Berg W.B. Expression of transforming growth factor-beta (TGFbeta) and the TGFbeta signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation. Ann. Rheum. Dis. 65 (2006) 1414-1421
39. Ito Y., Bringas Jr. P., Mogharei A., Zhao J., Deng C., and Chai Y. Receptor-regulated and inhibitory Smads are critical in regulating transforming growth factor beta-mediated Meckel's cartilage development. Dev. Dyn. 224 (2002) 69-78
40. Li T.F., Darowish M., Zuscik M.J., Chen D., Schwarz E.M., Rosier R.N., Drissi H., and O'Keefe R.J. Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation. J. Bone Miner. Res. 21 (2006) 4-16
41. Furumatsu T., Tsuda M., Taniguchi N., Tajima Y., and Asahara H. Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J. Biol. Chem. 280 (2005) 8343-8350
42. Kizawa H., Kou I., Iida A., Sudo A., Miyamoto Y., Fukuda A., Mabuchi A., Kotani A., Kawakami A., Yamamoto S., Uchida A., Nakamura K., Notoya K., Nakamura Y., and Ikegawa S. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat. Genet. 37 (2005) 138-144
43. Blaney Davidson E.N., Scharstuhl A., Vitters E.L., van der Kraan P.M., and van den Berg W.B. Reduced transforming growth factor-beta signaling in cartilage of old mice: role in impaired repair capacity. Arthritis Res. Ther. 7 (2005) R1338-R1347
44. Verrecchia F., Chu M.L., and Mauviel A. Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 276 (2001) 17058-17062
45. Akool E.-S., Doller A., Muller R., Gutwein P., Xin C., Huwiler A., Pfeilschifter J., and Eberhardt W. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway. J. Biol. Chem. 280 (2005) 39403-39416
46. Tardif G., Reboul P., Dupuis M., Geng C., Duval N., Pelletier J.P., and Martel-Pelletier J. Transforming growth factor-beta induced collagenase-3 production in human osteoarthritic chondrocytes is triggered by Smad proteins: cooperation between activator protein-1 and PEA-3 binding sites. J. Rheumatol. 28 (2001) 1631-1639
47. Leivonen S.K., Ala-Aho R., Koli K., Grenman R., Peltonen J., and Kahari V.M. Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells. Oncogene 25 (2006) 2588-2600
48. Yuan W., and Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J. Biol. Chem. 276 (2001) 38502-38510
49. Souchelnytskyi S., Tamaki K., Engstrom U., Wernstedt C., Ten Dijke P., and Heldin C.H. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J. Biol. Chem. 272 (1997) 28107-28115
50. Bau B., Haag J., Schmid E., Kaiser M., Gebhard P.M., and Aigner T. Bone morphogenetic protein-mediating receptor-associated Smads as well as common Smad are expressed in human articular chondrocytes but not up-regulated or down-regulated in osteoarthritic cartilage. J. Bone Miner. Res. 17 (2002) 2141-2150
51. Sirard C., Kim S., Mirtsos C., Tadich P., Hoodless P.A., Itie A., Maxson R., Wrana J.L., and Mak T.W. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling. J. Biol. Chem. 275 (2000) 2063-2070
52. Song C.Z., Siok T.E., and Gelehrter T.D. Smad4/DPC4 and Smad3 mediate transforming growth factor-beta (TGF-beta) signaling through direct binding to a novel TGF-beta-responsive element in the human plasminogen activator inhibitor-1 promoter. J. Biol. Chem. 273 (1998) 29287-29290
53. Zhang J., Tan X., Li W., Wang Y., Wang J., Cheng X., and Yang X. Smad4 is required for the normal organization of the cartilage growth plate. Dev. Biol. 284 (2005) 311-322
54. Jinnin M., Ihn H., Asano Y., Yamane K., Trojanowska M., and Tamaki K. Tenascin-C upregulation by transforming growth factor-beta in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene 23 (2004) 1656-1667
55. Sanchez-Elsner T., Ramirez J.R., Sanz-Rodriguez F., Varela E., Bernabeu C., and Botella L.M. A cross-talk between hypoxia and TGF-beta orchestrates erythropoietin gene regulation through SP1 and Smads. J. Mol. Biol. 336 (2004) 9-24
56. Datta P.K., Blake M.C., and Moses H.L. Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta -induced physical and functional interactions between smads and Sp1. J. Biol. Chem. 275 (2000) 40014-40019
57. Tsukada S., Westwick J.K., Ikejima K., Sato N., and Rippe R.A. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J. Biol. Chem. 280 (2005) 10055-10064
58. Ungefroren H., Lenschow W., Chen W.B., Faendrich F., and Kalthoff H. Regulation of biglycan gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein Kinase signaling downstream of Smad signaling. J. Biol. Chem. 278 (2003) 11041-11049
59. Watanabe H., de Caestecker M.P., and Yamada Y. Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells. J. Biol. Chem. 276 (2001) 14466-14473
60. Longobardi L., O'Rear L., Aakula S., Johnstone B., Shimer K., Chytil A., Horton W.A., Moses H.L., and Spagnoli A. Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF-beta signaling. J. Bone Miner. Res. 21 (2006) 626-636